Session 1: Introduction to Addiction - Definitions & Characteristics

1.1 What is Addiction? Beyond the Stereotype

The term "addiction" is often used loosely in everyday language to describe anything from a love of chocolate to excessive use of social media. However, in a clinical and psychological context, addiction is a specific and serious condition. It is a complex, chronic disease of the brain's reward, motivation, and memory systems. It is not a moral failing or a lack of willpower. A helpful way to conceptualize addiction is through the "Four Cs":

• Compulsion: An overwhelming urge to use a substance or engage in a behaviour, often against one's own better judgment.
• Craving: An intense psychological preoccupation with obtaining and using the substance or engaging in the behaviour.
• Consequences: Continuing the behaviour despite significant negative consequences in one's life (e.g., health problems, job loss, relationship breakdown).
• Control (Loss of): The inability to consistently abstain or control the frequency, amount, or duration of the behaviour.

1.2 Clinical Definitions: DSM-5 and ICD-11

To provide a standardized and reliable framework for diagnosis and research, clinicians use two main diagnostic manuals: the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the World Health Organization's International Classification of Diseases (ICD-11). Both manuals have moved away from the separate categories of "abuse" and "dependence," instead using the concept of a "Substance Use Disorder" (SUD) measured on a spectrum of severity (mild, moderate, severe).

1.3 The Concepts of Tolerance and Withdrawal

Two other key characteristics often associated with addiction are tolerance and withdrawal, which fall under the pharmacological criteria in the DSM-5:

• Tolerance: A need for markedly increased amounts of the substance to achieve the desired effect, or a markedly diminished effect with continued use of the same amount. For example, a person who once felt intoxicated after two drinks now needs five or six to feel the same way.
• Withdrawal: A characteristic set of unpleasant physical and psychological symptoms that occurs when the substance is discontinued or reduced. The person may then take the substance (or a similar one) to relieve or avoid these withdrawal symptoms. For example, a heavy coffee drinker might experience headaches, irritability, and fatigue if they miss their morning coffee.

It is crucial to understand that while tolerance and withdrawal are common in severe SUDs, they are neither necessary nor sufficient for a diagnosis. A person can be addicted without significant physical withdrawal (e.g., cannabis use disorder), and a person can experience withdrawal from a substance they are not addicted to (e.g., a patient taking prescribed opioid painkillers as directed). The core of addiction lies in the compulsive use and loss of control.

1.4 Applying the Definitions

Session 2: The Usefulness and Controversy of the Addiction Concept

2.1 Why Have a Concept of Addiction?

After establishing a clinical definition, a critical question arises: is this concept actually useful? The idea of "addiction" as a distinct category of behaviour serves several important functions:

• Clinical Utility: It provides a framework for diagnosis, allowing clinicians to identify individuals who need help and to develop targeted treatment plans. A diagnosis can grant access to healthcare services, insurance coverage, and support systems.
• Research Advancement: A clear, standardized definition allows researchers to study the causes, progression, and treatment of addiction in a systematic way. It enables communication and comparison of findings across different studies and populations.
• Personal Understanding: For many individuals, receiving a diagnosis of an addiction can be a profound relief. It provides a name for their suffering, helps them understand they are not alone, and can reduce feelings of shame by framing their problem as a medical condition rather than a moral failure.
• Social and Legal Framework: The concept of addiction informs public health policy, drug laws, and the legal system's approach to drug-related crime.

2.2 The Dark Side of the Label: Stigma and Oversimplification

Despite its utility, the concept of addiction is fraught with problems and controversy. Critics argue that the label itself can be harmful and that the concept is often oversimplified.

The stigma associated with being labeled an "addict" is a major barrier to seeking help. It can lead to discrimination in housing, employment, and social relationships. Furthermore, some argue that the label can become a harmful part of a person's identity, fostering a sense of powerlessness.

2.3 The Continuum vs. Categorical Debate

Perhaps the most significant scientific criticism of the addiction concept is its categorical nature. The label "addict" implies a black-and-white distinction: you either are one or you are not. However, modern research increasingly views substance use, and the problems associated with it, as existing on a continuum. The DSM-5's shift to a "Substance Use Disorder" with a severity rating (mild, moderate, severe) is a direct response to this criticism. It acknowledges that there is a vast grey area between occasional, non-problematic use and severe, compulsive addiction. The question remains: is it more useful to think of addiction as a discrete category or as the extreme end of a spectrum?

Analytical Question:

How might treating addiction as a continuum rather than a category change public health policy? For example, would it encourage more focus on harm reduction and early intervention for "mild" or "moderate" problems, rather than focusing only on severe cases?

2.4 Evaluating the Usefulness of the Concept

Session 3: Psychoactive Substances - Pleasure, Therapy, and the Reward Pathway

3.1 What Makes a Drug "Psychoactive"?

A psychoactive substance is any chemical that, when taken, alters brain function, resulting in changes in perception, mood, consciousness, cognition, or behaviour. This is a very broad category that includes everything from caffeine and nicotine to prescription medications and illegal drugs. The key feature is their ability to cross the blood-brain barrier and directly influence the central nervous system.

3.2 Two Sides of the Same Coin: Therapeutic vs. Recreational Use

Many psychoactive substances have a dual nature. The same drug can be a valuable therapeutic tool in one context and a dangerous substance of abuse in another. The distinction often lies in the dose, the route of administration, the user's intent, and the social and legal context.

• Therapeutic Use: The substance is used under medical supervision to treat a specific physical or psychological condition. The goal is to restore normal functioning. For example, amphetamines (like Adderall) are used to treat ADHD, and opioids (like morphine) are used to manage severe pain.
• Recreational Use (or "Pleasure Use"): The substance is used without medical justification, with the primary intent of altering one's state of consciousness to produce feelings of pleasure or euphoria. This is the type of use that can lead to a substance use disorder.

Analytical Question:

Cannabis is increasingly being legalized for both medical and recreational use. How does this dual legal status complicate our understanding of it as either a "medicine" or a "drug of abuse"?

3.3 The Brain's Pleasure Center: The Mesolimbic Dopamine Pathway

Why are some substances so powerfully reinforcing? The answer lies deep within the brain in a circuit known as the mesolimbic dopamine pathway, often called the "reward pathway." This is not a single spot, but a set of interconnected brain structures that are crucial for motivation, reinforcement learning, and survival. Its purpose is to make us repeat behaviours that are essential for life, such as eating, drinking, and procreating, by associating them with feelings of pleasure.

The key players in this pathway are:

• Ventral Tegmental Area (VTA): A group of neurons in the midbrain that produce dopamine.
• Nucleus Accumbens: A region in the forebrain that receives dopamine signals from the VTA. It is a major hub for processing reward and motivation.
• Prefrontal Cortex: The brain's executive center, which is involved in planning, decision-making, and regulating behaviour. It receives signals from the nucleus accumbens.

3.4 How Drugs "Hijack" the Reward Pathway

Addictive drugs are so powerful because they artificially and dramatically increase dopamine in the reward pathway. They "hijack" this natural system, creating a surge of pleasure far more intense and reliable than natural rewards. Different drugs do this in different ways:

• Stimulants (e.g., Cocaine, Amphetamines): Directly block the reuptake of dopamine, causing it to build up in the synapse and repeatedly stimulate the nucleus accumbens.
• Opioids (e.g., Heroin, Morphine): Inhibit neurons that normally suppress dopamine release, leading to an indirect but powerful surge of dopamine.
• Alcohol and Nicotine: Have more complex effects but also ultimately lead to increased dopamine release in the nucleus accumbens.

This artificial overstimulation teaches the brain that the drug is more important than natural rewards. Over time, the brain adapts to these massive dopamine surges by reducing its own dopamine production or decreasing the number of dopamine receptors. This leads to tolerance (needing more of the drug to get the same effect) and anhedonia (the inability to feel pleasure from natural rewards), driving the cycle of addiction.

Session 4: Classifying Drugs - Legal, Illegal, and their Psychoactive Effects

4.1 The Social Construction of Legality

A common misconception is that drugs are made illegal because they are scientifically proven to be the most dangerous. In reality, the legal status of a drug is a complex issue shaped by historical, cultural, political, and economic factors, not just pharmacology. For example, alcohol and tobacco are legal in most countries, yet they are responsible for far more deaths and societal harm than many illegal substances combined. Conversely, substances like psilocybin (magic mushrooms) and LSD, which have a very low potential for physical addiction and overdose, are strictly illegal in most places. It is essential to understand that legality is not a reliable indicator of a drug's potential for harm or addiction.

4.2 A Pharmacological Classification System

A more scientific way to classify drugs is based on their primary effect on the central nervous system (CNS). The three main categories are depressants, stimulants, and hallucinogens. Opiates are often considered a sub-category of depressants but are significant enough to warrant their own discussion.

4.3 A Closer Look at Common Drugs

• Alcohol: As a depressant, it reduces inhibitions and impairs judgment in low doses, while causing significant motor impairment and sedation at higher doses. It has a high potential for both addiction and severe physical withdrawal.
• Cocaine: A powerful stimulant that produces a short-lived but intense euphoria by blocking dopamine reuptake. It has a very high psychological addiction potential.
• Heroin: An opioid that creates a powerful rush of euphoria and pain relief. It has an extremely high potential for addiction and life-threatening overdose due to respiratory depression.
• Cannabis (Marijuana): A complex drug with mild depressant, stimulant, and hallucinogenic properties. Its primary psychoactive component, THC, affects the endocannabinoid system. While its physical withdrawal is typically mild, it can lead to a psychological dependence (Cannabis Use Disorder).

4.4 Applying Drug Classifications

Session 5: The Disease Model of Addiction - History and Evaluation

5.1 A Paradigm Shift: From Moral Failing to Medical Disease

For most of history, excessive substance use was viewed through a moral model. The "drunkard" or "addict" was seen as a person with a weak character, a sinful nature, or a lack of willpower. The solution was punishment, shame, or religious conversion. The mid-20th century saw a revolutionary shift in thinking with the emergence of the disease model of addiction. This model reframed addiction not as a choice, but as an involuntary, chronic, and progressive medical illness, similar to diabetes or heart disease.

5.2 The Pioneer: E.M. Jellinek and Alcoholism as a Disease

The disease model was popularized by the work of E.M. Jellinek in the 1940s and 50s. Based on his studies of members of Alcoholics Anonymous (A.A.), Jellinek proposed that alcoholism was a predictable, progressive disease with distinct phases. His work was groundbreaking because it moved the problem of alcoholism from the church and the jailhouse into the realm of medicine. He argued that the "alcoholic" was a sick person who deserved treatment, not a bad person who deserved punishment.

5.3 The Jellinek Curve: Mapping the Progression of Alcoholism

Jellinek's most famous contribution is the "Jellinek Curve," a U-shaped diagram that maps the progression of alcoholism and the potential path to recovery. While originally based on a specific subset of male alcoholics and now considered an oversimplification, it remains a powerful visual tool used in many treatment centers.

5.4 Evaluating the Disease Model

The disease model has had a profound and lasting impact on how society views and treats addiction. However, it is also heavily criticized for being oversimplified and potentially disempowering.

Session 6: The Brain Disease Model of Addiction (BDMA) - Scientific Evidence

6.1 The Modern View: Addiction as a Brain Disease

While Jellinek's model was a crucial social and political step, the modern Brain Disease Model of Addiction (BDMA) is a neurobiological theory grounded in decades of neuroscience research. It builds on the disease concept by identifying the specific, measurable changes in brain structure and function that are caused by chronic substance use and that underlie the symptoms of addiction. The BDMA argues that addiction is a disease of the brain's reward, stress, and self-control circuits.

6.2 The Addiction Cycle: A Three-Stage Neurobiological Model

Leading researchers, particularly from the National Institute on Drug Abuse (NIDA), have proposed a three-stage model to explain the neurobiology of the addiction cycle. This cycle becomes more and more severe over time as drugs physically alter the brain.

6.3 Deconstructing the Cycle: Brain Regions and Neurotransmitters

• Stage 1: Binge/Intoxication. This is the stage where a person consumes an intoxicating substance and experiences its rewarding or pleasurable effects.
  • Brain Circuits: Primarily involves the nucleus accumbens and the dorsal striatum.
  • Neurobiology: The drug causes a large and rapid increase in dopamine in the reward pathway, producing euphoria and "teaching" the brain to repeat the behaviour. Over time, the dorsal striatum becomes involved, turning the substance use into a compulsive, automatic habit.
• Stage 2: Withdrawal/Negative Affect. This stage occurs when the substance is no longer available, leading to a negative emotional and physical state.
  • Brain Circuits: Involves the amygdala (the brain's fear and anxiety center) and a decrease in the functioning of the reward system.
  • Neurobiology: The brain, having adapted to the drug-induced dopamine surges, now has a depleted reward system (the "anti-reward" system). This leads to dysphoria, anxiety, and irritability. The amygdala becomes overactive, producing a stress response. The person is no longer taking the drug to feel good, but to stop feeling bad.
• Stage 3: Preoccupation/Anticipation (Craving). This is the stage where a person seeks out the substance again after a period of abstinence.
  • Brain Circuits: Involves the prefrontal cortex (PFC), the brain's executive control center.
  • Neurobiology: The PFC, which is responsible for impulse control and decision-making, becomes impaired. The brain becomes hypersensitive to cues associated with the drug (e.g., seeing paraphernalia, being in a place where they used to use). These cues trigger intense craving and an impulsive drive to seek the drug, overriding the PFC's ability to say "no."

6.4 Applying the Neurobiological Model

Session 7: Critiques of the Disease Model & Alternative Perspectives

7.1 Is the Brain Disease Model the Whole Story?

The Brain Disease Model of Addiction (BDMA) is the dominant paradigm in addiction science and medicine. However, it is not without its powerful critics. While few dispute that chronic drug use changes the brain, many sociologists, psychologists, and philosophers argue that the BDMA is a form of neuro-reductionism—that is, it reduces a complex human problem to a simple matter of brain chemistry, ignoring the psychological, social, and existential dimensions of addiction.

7.2 Major Criticisms of the BDMA

• Biological Determinism: Critics argue the BDMA is overly deterministic. By saying "the brain made me do it," it can strip individuals of their sense of agency and power to change. If addiction is an automatic, compulsive brain process, where does choice fit in?
• The Problem of Recovery: A significant number of people with severe addiction recover without any formal treatment ("natural recovery"). If addiction is a chronic, progressive brain disease like Alzheimer's, how is this possible? This suggests that choice, motivation, and changes in life circumstances play a much larger role than a strict BDMA might suggest.
• Ignoring the "Why": The BDMA is excellent at explaining the "how" of addiction (the neurocircuitry), but critics say it's poor at explaining the "why." Why did the person start using heavily in the first place? The model often overlooks the role of trauma, poverty, mental health issues (like depression and anxiety), and lack of purpose that often drive addiction.

7.3 An Alternative Perspective: The Choice Model

As a counterpoint to the disease model, some theorists propose a choice model of addiction. This model does not necessarily deny the biological changes that occur but places a much stronger emphasis on human agency and rational decision-making. Key tenets include:

• Addiction as Learned Behaviour: Addiction is a learned pattern of behaviour that is reinforced over time. It is a habit, albeit a very powerful and destructive one.
• Time Preference: Addictive choices often reflect a strong preference for immediate gratification over long-term negative consequences. The person "chooses" the short-term pleasure of the drug, despite knowing the long-term costs.
• The Role of Values and Alternatives: People are less likely to choose drugs when they have access to meaningful alternative sources of reinforcement (e.g., a good job, strong relationships, engaging hobbies). Addiction often flourishes in the absence of better options. From this perspective, the solution is not just to "treat the brain" but to "build a life" that is more rewarding than substance use.

7.4 Comparing the Models

Session 8: Workshop - Evaluating Scientific Evidence for Theoretical Arguments

8.1 The Foundation of Theory: Evidence

The debate between the disease model and the choice model is not just a philosophical one; it is a scientific one that rests on evidence. But what counts as "evidence"? And how do we evaluate its quality? This session is a practical workshop designed to develop your skills in critically evaluating the scientific evidence used to support theoretical arguments about addiction. This directly addresses AC 2.2 and prepares you for the summative assessment.

8.2 Types of Evidence in Addiction Research

Addiction researchers use a variety of methods, each with its own strengths and limitations:

• Animal Studies: Researchers can model addictive behaviours in rodents (e.g., self-administration of drugs).
  • Strength: Allows for invasive techniques (e.g., measuring dopamine directly, genetic manipulation) that are impossible in humans. High degree of experimental control.
  • Weakness: The human experience of addiction is far more complex. Can we truly generalize from a rat pressing a lever to the social and psychological struggles of a human? (Low ecological validity).
• Neuroimaging Studies (fMRI, PET): These studies allow researchers to observe the human brain in action.
  • Strength: Provides direct evidence of brain changes associated with addiction (e.g., showing the PFC is less active during a craving).
  • Weakness: Mostly correlational. It shows which brain areas are associated with a behaviour, but doesn't prove they cause it. The technology is also extremely expensive and the tasks performed in a scanner can be artificial.
• Epidemiological/Correlational Studies: Large-scale surveys that look for relationships between variables in a population (e.g., the link between childhood trauma and adult addiction).
  • Strength: High real-world relevance (ecological validity). Can identify important risk factors.
  • Weakness: Correlation does not equal causation. It cannot prove that childhood trauma causes addiction, only that they are linked.

8.3 The Art of Critical Evaluation

When you encounter a piece of scientific evidence, you must think like a critic. Don't just accept the conclusion; question the method. Key questions to ask include:

• What is the specific claim being made?
• What type of evidence is being used to support it?
• What are the strengths of that type of evidence?
• What are the limitations or alternative explanations for the findings?
• Does the evidence really support the claim being made?

8.4 Workshop: Evaluating the Evidence

Session 9: Introduction to Risk Factors - A Biopsychosocial Approach

9.1 Why Do Some People Become Addicted and Others Don't?

This is one of the most fundamental questions in addiction science. If two people try the same drug, why might one go on to develop a severe addiction while the other does not? The answer is that addiction is not caused by a single factor. There is no single "addiction gene" or "addictive personality." Instead, addiction results from a complex interplay of multiple risk factors. The best framework for understanding this complexity is the biopsychosocial model.

9.2 The Biopsychosocial Model of Addiction

The biopsychosocial model is a holistic perspective that posits that health and illness are determined by the dynamic interaction of biological, psychological, and social factors. It moves away from simple, linear explanations ("genes cause addiction") to a more comprehensive, multi-layered understanding.

9.3 The "Swiss Cheese" Model of Cumulative Risk

A useful metaphor for understanding how these factors interact is the "Swiss Cheese Model," often used in accident analysis. Imagine a stack of Swiss cheese slices. Each slice represents a layer of protection (e.g., stable family, good mental health, no genetic risk). The holes in each slice represent a risk factor. An adverse outcome—like the development of addiction—occurs only when the holes in all the slices line up, allowing a trajectory of risk to pass through all the layers of protection.

This model illustrates a key concept: cumulative risk. It's rarely one thing that leads to addiction, but rather the accumulation of multiple risk factors across the biological, psychological, and social domains. Conversely, protective factors (like a supportive family or strong coping skills) can "block the holes" and prevent addiction even in the presence of other risks.

9.4 Applying the Biopsychosocial Model

Session 10: Social and Environmental Risk Factors

10.1 The Power of Context

While biology and psychology are important, they don't happen in a vacuum. The social and environmental context in which a person lives is a powerful determinant of their risk for developing an addiction. This session explores these "nurture" factors, from broad cultural influences to the immediate impact of family and peers.

10.2 Macro-Level Factors: Culture, Availability, and Socioeconomics

• Cultural and Social Norms: Cultures vary widely in their attitudes towards substance use. In some cultures, heavy drinking is a normalized part of socializing (e.g., the UK), while in others, it is strongly condemned (e.g., many Islamic cultures). These norms shape expectancies, influence the age of first use, and determine the level of social acceptance or stigma.
• Availability: The simple principle of availability is a major risk factor. People are more likely to use drugs that are cheap, easy to obtain, and prevalent in their community. This is why addiction rates are often higher in urban areas with established drug markets.
• Socioeconomic Status (SES): Poverty, lack of education, and unemployment are strongly correlated with higher rates of addiction. This is not because people in poverty have weaker morals, but because they face higher levels of stress, have fewer resources for coping, and may have less access to rewarding alternatives to substance use.

10.3 Micro-Level Factors: Family and Peers

The immediate social environment of family and peers is one of the most powerful predictors of substance use, especially during adolescence.

10.4 Applying Social Risk Factors

Session 11: Individual and Psychological Risk Factors

11.1 The Internal Landscape: Psychology and Personality

While the social environment provides the context, individual psychological factors and personality traits play a crucial role in determining a person's vulnerability to addiction. Why do some people thrive in high-stress environments while others turn to substances? Why are some people more drawn to risky behaviours than others? This session explores the internal, psychological landscape of addiction risk.

11.2 Co-Occurring Disorders: The Dual Diagnosis Problem

One of the strongest predictors of developing a substance use disorder is the presence of another mental health condition. This is often referred to as co-occurring disorders or dual diagnosis. The relationship is complex and can work in several ways:

• Self-Medication Hypothesis: Individuals may use substances to cope with the symptoms of a mental health disorder. For example, a person with social anxiety might use alcohol to feel more comfortable in social situations, or a person with depression might use stimulants to combat lethargy.
• Shared Risk Factors: The same underlying factors (e.g., genetic predispositions, childhood trauma) might increase the risk for both addiction and other mental illnesses.
• Substance-Induced Disorders: Chronic substance use can directly cause or worsen mental health problems. For example, heavy cannabis use can trigger psychosis in vulnerable individuals, and chronic alcohol use can lead to depression.

Common co-occurring disorders include depression, anxiety disorders, PTSD, and personality disorders.

11.3 The Role of Stress and Trauma

Exposure to high levels of stress, particularly chronic or traumatic stress, is a major psychological risk factor. Stress impacts the same brain circuits involved in addiction, particularly the prefrontal cortex and the stress-response system (the HPA axis). Individuals who have experienced significant trauma (e.g., abuse, violence, combat) have a much higher risk of developing addiction, often as a way to numb emotional pain or manage the symptoms of PTSD.

11.4 Personality Traits and Vulnerability

While there is no single "addictive personality," research has identified several personality traits that are consistently linked to a higher risk of substance use disorders:

• High Impulsivity: The tendency to act on a whim with little thought for future consequences.
• High Sensation-Seeking: A strong need for varied, novel, and intense experiences and the willingness to take physical and social risks for the sake of such experiences.
• High Neuroticism: A personality trait characterized by anxiety, moodiness, worry, envy, and jealousy. Individuals high in neuroticism may be more likely to use substances to cope with their negative emotional states.

One influential model is Cloninger's Tridimensional Theory of Addictive Behaviour, which proposes that vulnerability to addiction is influenced by three key personality dimensions:

1. Novelty Seeking: A tendency towards excitement in response to new stimuli, which correlates with impulsivity and sensation-seeking. (Linked to low dopamine activity).
2. Harm Avoidance: A tendency to respond intensely to aversive stimuli, leading to worry and fear. (Linked to high serotonin activity).
3. Reward Dependence: A tendency to respond intensely to signals of reward (especially social approval) and to maintain behaviour that has been previously rewarded. (Linked to low norepinephrine activity).

Cloninger proposed that different combinations of these traits could predict the risk for different types of addiction (e.g., high novelty-seeking predicting early-onset alcoholism).

Session 12: Ethical Issues in Addiction Research

12.1 A Vulnerable Population

Research is essential for advancing our understanding and treatment of addiction. However, conducting research with individuals who have substance use disorders presents a unique and complex set of ethical challenges. People with active addictions are considered a vulnerable population in research ethics. This is because their ability to make fully informed and voluntary decisions may be compromised by factors such as cognitive impairment from drug use, the compulsion to obtain drugs, or socioeconomic desperation.

12.2 Core Ethical Principles in Addiction Research

All human research is guided by core ethical principles, but they take on special significance in the context of addiction:

• Informed Consent: Participants must fully understand the risks and benefits of a study before they agree to participate.
  • The Challenge: Can a person who is intoxicated or experiencing severe withdrawal give truly informed consent? Is the promise of payment (even a small amount) unduly coercive for someone who is homeless and needs money for drugs?
• Beneficence and Non-Maleficence (Do Good, Do No Harm): The potential benefits of the research must outweigh the risks to the participant.
  • The Challenge: In a study that involves administering a drug, is the researcher causing harm? How can researchers minimize risks, such as the risk of relapse for someone in recovery?
• Confidentiality: The identity and data of research participants must be protected.
  • The Challenge: Because substance use is often illegal, a breach of confidentiality could have severe legal consequences for the participant. Researchers often need special legal protections (a "Certificate of Confidentiality") to avoid being forced to turn over their data to law enforcement.
• Stigma: Researchers have a duty to conduct and report their findings in a way that does not increase the stigma associated with addiction.

12.3 The Placebo Problem

One of the most difficult ethical issues in clinical trials for addiction treatment is the use of a placebo control group. The "gold standard" for testing a new medication is a randomized controlled trial (RCT) where one group gets the new drug and another group gets a placebo (a sugar pill). However, is it ethical to give a placebo to a person seeking help for a life-threatening condition, thereby denying them a potentially effective treatment for the duration of the study?

To manage this, researchers often use an "active control," where the new drug is compared to the current standard treatment rather than a placebo. This ensures that no one is denied treatment altogether.

12.4 Workshop: Navigating Ethical Dilemmas

Session 13: Overview of Treatment Approaches & The Role of Detoxification

13.1 No Single Path to Recovery

Just as there is no single cause of addiction, there is no single "cure." Effective treatment must be tailored to the individual's specific needs, addressing their unique combination of biological, psychological, and social problems. Modern addiction treatment is best understood as a continuum of care, with different levels of intensity and support.

13.2 The Continuum of Care

Treatment can range from brief interventions to long-term residential care:

• Early Intervention: Brief counseling or advice given by a GP or other professional for individuals with mild or at-risk substance use.
• Outpatient Treatment: The most common form of treatment. Individuals live at home but attend regular therapy sessions (individual or group) at a clinic.
• Intensive Outpatient (IOP) / Partial Hospitalization (PHP): A more structured level of care, involving several hours of therapy per day, several days a week. It provides more support than standard outpatient but still allows the person to live at home.
• Residential/Inpatient Treatment: The individual lives at the treatment facility for a period (typically 30-90 days), receiving intensive therapy in a highly structured, substance-free environment.
• Medically Managed Inpatient Treatment: The highest level of care, for individuals with severe, unstable medical or psychiatric conditions alongside their addiction.

13.3 The First Step: Detoxification

For many individuals with physical dependence on a substance, the first step before engaging in psychological therapy is detoxification (detox). Detox is the process of safely managing the acute physical symptoms of withdrawal that occur when a person stops using a substance. This is often done under medical supervision, where medications can be used to ease the symptoms and prevent dangerous complications.

It is absolutely critical to understand that detox is not treatment. It is a preparatory step. Detox manages the physical crisis of withdrawal, but it does nothing to address the underlying psychological, social, and behavioural problems that caused the addiction in the first place. A person who only completes detox without engaging in further therapy has an extremely high probability of relapsing.

13.4 The Dangers of Withdrawal

Medical supervision during detox is particularly important for two classes of drugs:

• Alcohol and Benzodiazepines: Withdrawal from these depressants can be life-threatening. It can cause seizures, hallucinations (delirium tremens or "the DTs"), and cardiovascular collapse. Abruptly stopping heavy, long-term use without medical help is extremely dangerous.
• Opiates: While opiate withdrawal (e.g., from heroin or fentanyl) is not typically life-threatening, it is intensely unpleasant, with severe flu-like symptoms, pain, and cramping. The misery of withdrawal is a major driver of relapse.

Session 14: Psychological Therapies Part 1 - CBT and Motivational Interviewing

14.1 The "Software" of Recovery: Changing Thoughts and Behaviours

If addiction is a disease of the brain, psychological therapies are the "software updates" designed to help rewire it. These therapies don't just involve talking; they are structured, evidence-based interventions that teach individuals concrete skills to manage cravings, change destructive thought patterns, and build a life in recovery. This session focuses on two of the most widely used and effective psychological therapies: Cognitive Behavioural Therapy (CBT) and Motivational Interviewing (MI).

14.2 Cognitive Behavioural Therapy (CBT) for Addiction

Cognitive Behavioural Therapy (CBT) is a type of psychotherapy based on the idea that our thoughts, feelings, and behaviours are interconnected, and that changing negative thought patterns can lead to changes in behaviour. In the context of addiction, CBT helps individuals identify and change the dysfunctional thoughts and beliefs that contribute to their substance use.

14.3 Motivational Interviewing (MI): Resolving Ambivalence

Many people with addiction are ambivalent about changing. Part of them wants to stop, but another part of them doesn't. A traditional, confrontational approach ("You have to quit!") often backfires, making the person defensive. Motivational Interviewing (MI) is a collaborative, person-centered counseling style designed to explore and resolve this ambivalence. It is not about persuading the person to change, but about helping them find their own motivation to change.

MI is guided by a "spirit" of partnership, acceptance, compassion, and evocation (drawing out the person's own wisdom). The core skills are summarized by the acronym OARS:

• Open-ended questions: Questions that can't be answered with a simple "yes" or "no" (e.g., "What are some of the things you don't like about your drinking?").
• Affirmations: Recognizing the person's strengths and efforts ("It took a lot of courage to come here today.").
• Reflective listening: Listening carefully and reflecting back what the person has said, often highlighting their own "change talk" (e.g., "So on the one hand, you enjoy the social aspect of drinking, but on the other, you're worried about its effect on your health.").
• Summaries: Pulling together the key points of the conversation, again with a focus on the person's own motivations for change.

14.4 Applying the Therapies

Session 15: Psychological Therapies Part 2 - Behavioural and Systemic Approaches

15.1 Beyond Cognition: Changing Behaviour and Systems

While CBT and MI focus on the internal world of thoughts and motivations, other therapies focus more directly on changing behaviour through conditioning or on changing the social system in which the individual lives. This session explores these behavioural and systemic approaches, including aversion therapy, contingency management, and family and group therapy.

15.2 Behavioural Therapies: Conditioning Sobriety

Behavioural therapies are based on the principles of classical and operant conditioning. They aim to change the addictive behaviour directly by altering its associated rewards and punishments.

• Aversion Therapy: This therapy uses classical conditioning to create a negative association with the substance. The goal is to pair the substance (or thoughts of it) with an unpleasant stimulus.
  • Example: A person with alcohol use disorder might be given a drug (an emetic) that causes severe nausea and vomiting, and then be required to drink alcohol. After several pairings, the sight and smell of alcohol alone can trigger a conditioned response of nausea, reducing the desire to drink. This approach is controversial and less common today due to its unpleasant nature.
• Contingency Management (CM): This therapy uses operant conditioning to reinforce desired behaviours (like abstinence). It is based on the simple principle that behaviour that is rewarded is more likely to be repeated.
  • Example: In a CM program, a client might provide a urine sample several times a week. For every sample that is negative for drugs, they receive a reward, such as a voucher or a chance to win a prize. The rewards often start small and increase in value with consecutive clean samples. CM has been shown to be highly effective, particularly for stimulant addiction.

15.3 Systemic Therapies: The Person in Context

Systemic therapies recognize that an individual's addiction does not exist in isolation. It affects, and is affected by, the social systems they are part of, particularly their family and peer group.

• Family Therapy: Addiction is often called a "family disease" because it profoundly impacts family dynamics. Family therapy works with the entire family unit, not just the person with the addiction. The goals are to improve communication, establish healthy boundaries, and help family members understand how their own behaviours (e.g., enabling, codependency) might be contributing to the problem.
• Group Therapy and Peer Support: Group therapy, led by a therapist, allows individuals to share their experiences and learn from others facing similar struggles. Peer support programs, like Alcoholics Anonymous (A.A.) or Narcotics Anonymous (N.A.), are not formal therapy but are a cornerstone of recovery for millions. They leverage the power of shared experience, mutual support, and modeling of sober behaviour to help people maintain abstinence.

15.4 Applying Different Therapeutic Models

Session 16: Biological Therapies - Pharmacotherapy and Brain Stimulation

16.1 The "Hardware" of Recovery: Treating the Brain Directly

If addiction is a brain disease, it follows that we should have medicines to treat it. Pharmacotherapy involves using medications to help manage addiction. These medications are not a "cure," but they can be powerful tools to reduce cravings, manage withdrawal, and prevent relapse, often used in combination with psychological therapies. This session explores the main pharmacological strategies and emerging brain stimulation techniques.

16.2 Three Main Strategies of Pharmacotherapy

Medications for addiction generally work in one of three ways:

16.3 Medication-Assisted Treatment (MAT) for Opioid Addiction

The most prominent use of pharmacotherapy is in Medication-Assisted Treatment (MAT) for opioid use disorder. This is a highly effective, evidence-based approach that combines medication with counseling and behavioural therapies.

• Methadone: A long-acting opioid agonist. It must be dispensed daily at a specialized clinic. It relieves withdrawal and cravings, allowing people to stop using illicit opioids and stabilize their lives.
• Buprenorphine (Suboxone): A partial opioid agonist. It has a "ceiling effect," making it safer and with less overdose potential than methadone. It can be prescribed by a doctor and taken at home.
• Naltrexone: An opioid antagonist. It completely blocks the effects of opioids. It is best for highly motivated individuals who are already detoxified, as it can precipitate severe withdrawal if opioids are still in the person's system.

MAT is often controversial, with some critics incorrectly viewing it as "substituting one addiction for another." However, scientific consensus is clear: MAT is a life-saving medical treatment that dramatically reduces illicit drug use, overdose deaths, and the spread of infectious diseases.

16.4 Emerging Technologies: Brain Stimulation

As our understanding of the neurocircuitry of addiction improves, researchers are exploring ways to directly modulate the brain circuits that are dysfunctional in addiction. These techniques are still largely experimental but hold future promise:

• Transcranial Magnetic Stimulation (TMS): A non-invasive technique that uses a powerful magnetic coil placed on the scalp to stimulate or inhibit activity in a specific brain region. In addiction research, TMS is often used to target the prefrontal cortex to try to enhance self-control and reduce cravings.
• Deep Brain Stimulation (DBS): An invasive surgical procedure where electrodes are implanted deep within the brain (e.g., in the nucleus accumbens). These electrodes deliver continuous electrical pulses to modulate the activity of that brain circuit. Due to its risks, DBS is only being explored for the most severe, treatment-resistant cases of addiction.

Session 17: Non-Chemical (Behavioural) Addictions

17.1 Can You Be Addicted to a Behaviour?

So far, we have focused on addiction to substances. But can a person be addicted to a behaviour? The concept of behavioural addiction (or process addiction) proposes that individuals can develop a compulsive, out-of-control relationship with certain behaviours that produce a short-term reward, leading to significant negative consequences. This is a controversial but rapidly growing area of psychology.

17.2 Gambling Disorder: The First Official Behavioural Addiction

For a long time, pathological gambling was classified as an "Impulse-Control Disorder." However, in a landmark decision, the DSM-5 reclassified it as Gambling Disorder and placed it in the chapter on "Substance-Related and Addictive Disorders." This was the first time a non-substance-related behaviour was officially recognized as an addiction. The rationale was the overwhelming evidence that Gambling Disorder looks remarkably similar to a substance use disorder:

• Symptoms: The diagnostic criteria for Gambling Disorder mirror those for SUDs, including loss of control, preoccupation, tolerance (needing to bet more and more money to get the same thrill), withdrawal (feeling restless or irritable when trying to stop), and continuing despite severe negative consequences.
• Neurobiology: Neuroimaging studies show that the brains of people with Gambling Disorder react to gambling cues in the same way that the brains of people with cocaine addiction react to drug cues—with heightened activation in the reward pathway.
• Comorbidity: Gambling Disorder has a very high rate of co-occurrence with substance use disorders.

17.3 The "Internet Addiction" Debate

What about other behaviours? The most debated potential behavioural addiction is Internet Gaming Disorder, which was included in the appendix of DSM-5 as a condition requiring further study. Proponents argue that some individuals' relationship with online gaming shows all the classic signs of addiction: compulsion, loss of control, withdrawal symptoms when not playing, and severe impairment in social, occupational, and academic functioning. Opponents argue that this is over-pathologizing a common hobby and that the problem is often a symptom of other underlying issues, like depression or social anxiety, rather than a primary addiction itself.

Other proposed behavioural addictions include compulsive shopping, sex addiction, and exercise addiction, though none of these are currently recognized as formal diagnoses in the DSM-5.

17.4 Comparing Substance and Behavioural Addictions

Session 18: Critical Evaluation of Addictive Behaviour Evidence

18.1 Thinking Like a Scientist

This session serves as a capstone for the unit, bringing together our knowledge of addiction theories with the critical evaluation skills we have been developing. The ability to read a research paper, understand its methods, and critically assess its conclusions is the single most important skill in psychology. Today, we will practice this skill in preparation for both of your final assignments.

18.2 The Challenge of "Proof" in Addiction Science

As we've seen, the evidence for any single theory of addiction is complex and often contradictory. There is no single study that "proves" the disease model or the choice model. Instead, scientists build a case by looking for a convergence of evidence from many different types of studies. A strong theory is one that is supported by findings from animal research, neuroimaging, genetic studies, and clinical trials. A critical thinker must be able to weigh the strengths and weaknesses of each piece of evidence to evaluate the overall strength of a theoretical argument.

18.3 A Framework for Critical Evaluation

Let's revisit the framework from Session 8. When you read a study, you should ask:

1. Research Question: What were the authors trying to find out? What was their hypothesis?
2. Methodology: Who were the participants? Was it an experiment or a correlational study? How were the key concepts (e.g., "craving," "recovery") operationalized and measured?
3. Findings: What were the main results? Were they statistically significant?
4. Interpretation: How did the authors interpret their findings? Do you agree with their interpretation?
5. Limitations: What are the study's weaknesses? (e.g., small sample size, lack of a control group, potential for bias, low ecological validity).
6. Implications: What are the broader implications of the findings for theory, treatment, or policy?

18.4 Workshop: Critiquing an Addiction Study